G
Gaby Danan
Researcher at Roussel Uclaf
Publications - 15
Citations - 2469
Gaby Danan is an academic researcher from Roussel Uclaf. The author has contributed to research in topics: Pharmacovigilance & Medicine. The author has an hindex of 6, co-authored 12 publications receiving 2280 citations.
Papers
More filters
Journal ArticleDOI
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.
Gaby Danan,Christian Bénichou +1 more
TL;DR: In this paper, a new method for drug causality assessment is described and applied to reports of acute liver injuries, using reports with positive rechallenge as external standard.
Journal ArticleDOI
Acute generalized exanthematous pustulosis. Analysis of 63 cases.
Jean-Claude Roujeau,Paulette Bioulac-Sage,Catherine Bourseau,Jean-Claude Guillaume,Philippe Bernard,Catherine Lok,Patrice Plantin,Alain Claudy,Carole Delavierre,Loïc Vaillant,Janine Wechsler,Gaby Danan,Christian Bénichou,Claire Beylot +13 more
TL;DR: It is suggested that some cases previously reported as "drug-induced pustular psoriasis" were in fact AGEP, a reaction pattern favored by a "psoriatic background" and added to the list of cutaneous adverse drug reactions.
Journal ArticleDOI
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.
TL;DR: It is concluded that adverse drug reaction reports with a positive rechallenge can provide a standard for validation of causality assessment methods, and RUCAM applied to drug-induced liver injuries has been validated.
Journal ArticleDOI
Proposed improvement to the WHO adverse reaction terminology (WHO‐ART)
Journal ArticleDOI
Experts' Opinion in Causality Assessment: Results of Consensus Meetings
Christian Bénichou,Gaby Danan +1 more
TL;DR: A first international consensus on drug-induced liver disorders has been recently obtained in Paris after French consensus meetings with university experts and specialists in industrial or official pharmacovigilance.